VLP Therapeutics

About VLP Therapeutics

This author has not yet filled in any details.
So far VLP Therapeutics has created 52 blog entries.

Journal of Virology – 27 September 2017

2017-10-09T00:57:38+00:00 2017.09.27|

“Envelope-modified tetravalent dengue virus-like particle vaccine: implication for flavivirus vaccine design” Akane Urakamia, Mya Myat Ngwe Tunb, Meng Ling Moib, Atsuko Sakuraia, Momoko Ishikawaa, Sachiko Kunoa, Ryuji Uenoa, Kouichi Moritab and Wataru Akahata   http://jvi.asm.org/content/early/2017/09/21/JVI.01181-17.abstract

VLP Therapeutics Appoints Jacob Licht as Chief Operating Officer

2017-07-22T06:05:57+00:00 2017.07.21|

Gaithersburg, Md. — July 21, 2017 — VLP Therapeutics, LLC (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced the appointment of Jacob Licht as Chief Operating Officer. Mr. Licht comes to VLP Therapeutics with nearly 20 years of business development and strategy experience

Clinical and Vaccine Immunology – July 2017, Volume 24, Issue 7

2017-10-09T00:57:52+00:00 2017.07.01|

“Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus” Akane Urakami, Atsuko Sakurai, Momoko Ishikawa, Moh Lan Yap, Yevel Flores-Garcia, Yasunari Haseda, Taiki Aoshi, Fidel P. Zavala, Michael G. Rossmann, Sachiko Kuno,a Ryuji Ueno, Wataru Akahata http://cvi.asm.org/content/24/7/e00090-17.full.pdf+html

VLP Therapeutics Announces Convertible Note Investment from TomyK Ltd. for Accelerating Cancer Vaccine Development

2017-05-10T01:37:00+00:00 2017.05.09|

Gaithersburg, Md. — May 9, 2017 — VLP Therapeutics, LLC (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced that it completed a convertible note financing with an angel investor Dr. Tomy Kamada, through his investment firm TomyK Ltd., that supports technology startups which

VLP Therapeutics Receives Notice of Allowance of Key U.S. composition of matter Patent for immune checkpoint PD-1/PD-L1/PD-L2 inserted alphavirus VLP

2017-04-21T10:19:52+00:00 2017.04.19|

Patent covers a composition of matter for immune checkpoint PD-1/PD-L1/PD-L2 inserted alphavirus VLP and method of use for cancer therapy Gaithersburg, Md. — April 19, 2017 — VLP Therapeutics, LLC. (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced that it successfully received a

VLP Therapeutics Appoints Danai Brooks, Managing Partner of Glen Echo Capital, to Advisory Board

2017-03-01T20:11:46+00:00 2017.03.01|

Gaithersburg, Md. — February 27, 2017 — VLP Therapeutics, LLC. (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced that Danai Brooks, Managing Partner of Glen Echo Capital, has agreed to join VLP’s Advisory Board.  Mr. Brooks is an experienced biotechnology executive, having led

VLP Therapeutics Receives Grant from Global Health Innovative Technology (GHIT) Fund to Develop New Vaccine for Dengue Fever

2017-01-11T00:18:17+00:00 2016.10.05|

Gaithersburg, Md.-- (PR NEWS WIRE) — October 5, 2016 -- VLP Therapeutics, LLC. announced today that it has received a grant for approximately US$960,000 from the Global Health Innovative Technology Fund (“the GHIT Fund”) for early-stage research to develop new vaccines for dengue fever using virus-like particles that would target all four strains of the